BIOMAT Database Logo BIOMAT Database Logo

Lipid formulations of amphotericin B. 2000

S P Dix, and V T Andriole
Saint Luke's Hospital of Kansas City, Missouri, USA.

The incidence of systemic fungal infections, especially in immunocompromised patients, has continued to increase during the past few decades. Treatment with conventional amphotericin B has been the standard care for the majority of patients with invasive fungal infections, despite its associated toxicity. Three lipid formulations of amphotericin B have now been approved for use in the United States. The pharmacology, pharmacokinetics, clinical experience, toxicity, dosing strategies, and cost of these three preparations--amphotericin B lipid complex, amphotericin B colloidal dispersion, and liposomal amphotericin B--were reviewed in detail in this chapter. The clinical data indicate that lipid formulations of amphotericin B represent an important therapeutic modality in the management of invasive fungal infections.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost
D005335 Fever of Unknown Origin Fever in which the etiology cannot be ascertained. Unknown Origin Fever,Unknown Origin Fevers
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D017850 Economics, Pharmaceutical Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1)) Pharmaceutical Economics,Pharmacoeconomics,Pharmacy Economics,Economic, Pharmacy,Economics, Pharmacy,Pharmacy Economic

Related Publications

S P Dix, and V T Andriole
Lipid formulations of amphotericin B.
September 1998, Cleveland Clinic journal of medicine,
S P Dix, and V T Andriole
Lipid-based formulations of amphotericin B.
May 1995, The Journal of antimicrobial chemotherapy,
S P Dix, and V T Andriole
The lipid formulations of amphotericin B.
August 2003, Expert opinion on pharmacotherapy,
S P Dix, and V T Andriole
Lipid-based formulations of amphotericin B.
February 2004, Drugs of today (Barcelona, Spain : 1998),
S P Dix, and V T Andriole
Lipid-based formulations of amphotericin B.
March 2000, Journal of the American Veterinary Medical Association,
S P Dix, and V T Andriole
[Amphotericin B and its lipid formulations].
January 2002, Mycoses,
S P Dix, and V T Andriole
Amphotericin B and its lipid formulations.
July 1994, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
S P Dix, and V T Andriole
Biopharmaceutical aspects of lipid formulations of amphotericin B.
January 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
S P Dix, and V T Andriole
Overview of the lipid formulations of amphotericin B.
February 2002, The Journal of antimicrobial chemotherapy,
S P Dix, and V T Andriole
Levels of amphotericin B lipid formulations in ascites.
November 2008, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!